LEVON RESOURCES Forum: Community User: Summer.76

Danke odi001!

https://www.smarteranalyst.com/analyst-insights/3-biotech-stocks-under-5-with-massive-upside-potential/

VBI Vaccines (VBIV) Using its enveloped virus-like particle (eVLP) platform, VBI Vaccines develops vaccines that could be capable of addressing unmet needs in infectious disease and immuno-oncology. With one analyst, Canaccord Genuity’s John Newman, expecting a “catalyst-rich” second half of the year for the company, its $2.49 share price could mean that now is the time to pull the trigger. The five-star analyst tells investors the fourth quarter of 2020 will see VBIV submit regulatory approval filings for Sci-B-Vac, its vaccine against hepatitis B. These will be comprised of data from the CONSTANT and PROTECT Phase 3 trials in the U.S., Europe and Canada. “We continue to expect the agencies will view Sci-B-Vac’s regulatory applications favorably and expect approvals in 2021…We continue to believe a key factor for VBIV will be whether the Advisory Committee on Immunization Practices (ACIP) recommends Sci-B-Vac at a two-dose immunization schedule, for their commercial launch,” he commented. As for its chronic hepatitis B virus (HBV) therapy, VBI-2601, initial human proof-of-concept data from the Phase 1b/2a study could be published in the second half of this year as well. Looking at its VBI-1901 asset, which was designed for use in recurrent Glioblastoma Multiforme (rGBM) patients, expanded immunologic, tumor and clinical data from the GM-CSF arm and initial immunologic and tumor response data from the AS01B arm are slated for release mid-year and in Q4, respectively. “We look for continued positive data for VBI-1901 in GBM,” Newman said. If that wasn’t enough, a pan-coronavirus vaccine is in the works, with VBIV expecting IND-enabling animal testing for the candidate, VBI-2901, to start in the second quarter. On top of this, the company could have clinical candidates selected and enough clinical supply ready in Q4 2020. As VBIV’s operations through 2021 will most likely be supported by the $57.5 million equity raise last month and its $35.8 million in cash as of Q1 2020, it’s no wonder Newman is optimistic. In addition to maintaining a Buy recommendation, he did trim the price target by $1 to account for share dilution. That being said, the $3 figure still leaves room for a possible twelve-month gain of 20%. (To watch Newman’s track record, click here) Do other analysts agree with Newman? As it turns out, they do. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: VBIV is a Strong Buy. At $4.33, the average price target is more aggressive and suggests 74% upside potential. (See VBI Vaccines stock analysis on TipRanks) https://www.smarteranalyst.com/analyst-insights/3-biotech-st…

http://stocktwits.com/TheWyseKid/message/213883748

2,75 schon im pre

Wie die schön läuft :)

Mach ich versprochen.... Du bekommst dann ein Päckchen zugeschickt 😉

Nicht zu früh, mach das, wenn wir bei 2,70 oder höher sind ;)

Und ich danke dir Ali 👍

Und danke odi!

👋

Hallo Jungs👋... Ich leiste euch mal Gesellschaft 🤗

Oh alles klar sorry, Fehler schon gefunden

Bei meinem Broker steht die Aktie bei 2,98 Euro, wie kann das sein?

f. o. o. l

https://www.***.com/investing/2020/05/17/is-buying-a-basket-loaded-with-every-coronavirus-v.aspx